Resources for coping with cancer during COVID-19. Learn More

Risky Business: On distinguishing low-risk from high-risk prostate cancer

November 27th, 2013

Written by Dr. Stuart Edmonds, Vice President, Research, Health Promotion and Survivorship

In September, PCC released recommendations with one overarching goal: for more men to get tested for prostate cancer. Currently, the test that is initially used for the early detection of prostate cancer is the Prostate Specific Antigen (PSA) test. It is a simple blood test that detects the levels of a protein released by the prostate when it is under stress. As a test for conditions affecting the prostate, it works fine. As a means to reliably detect prostate cancer, however, it is not perfect, just as mammography is not always reliable in detecting breast cancer. That is why, to confirm accurately a diagnosis of prostate cancer, the PSA blood test must be repeated and backed up with other diagnostic procedures such at the digital rectal exam (DRE), a biopsy and, increasingly more commonly, an MRI.

Early Warning Sign

Despite the shortcomings of the PSA test, physicians do not have many other early detection tests available in their clinics right now to choose instead. While other approaches being developed such as the Prostate Health Index (PHI) or the T2:ERG urine test offer great promise, the PSA test currently remains the only early warning sign available in clinical practice today. Such a red flag, especially when discovered early on, can be the indicator required to allow patients and physicians to explore the issue further and save lives. ‎

Different Forms of Cancer

‎However, we know that prostate cancer comes in multiple forms. A study led by Dr. Alexander Zlotta and funded by Prostate Cancer Canada recently reported that nearly 50% of men over 60 had prostate cancer at their time of death, but died of other causes.‎ This study reinforces the challenge discussed frequently today, which is the difficulty in distinguishing between prostate cancers that are indolent, or low-risk, and those that are aggressive, or high-risk. We often hear indolent cancers being described as those that men die with – in other words, it wasn’t the prostate cancer that was the cause of death, but rather another factor. Such cancers may not ever progress to the point to be life-threatening, and may not even need treatment. There is, however, the other end of the spectrum – those aggressive cancers that men die from. In other words, those aggressive prostate cancers are the ones that cause death and do need treatment. Current therapies can be very effective in saving lives - the death rates in Canada due to prostate cancer have been declining over the past eight years due in part to this. However they can lead to serious side effects such as incontinence and erectile dysfunction so it is especially important that we endeavour to treat only those that need to be treated and monitor those that do not. How can we make progress on this issue?

Taking Action, Searching For A Solution

In developing our research strategic plan, we heard from patients, survivors, researchers and clinicians that the number one issue to tackle with research is determining which men to treat and which to monitor. We listened intently to this feedback and this month launched a new research program funded by Movember that addresses this specific problem. ‎It’s putting resources to answer the question most pressing in the field of prostate cancer diagnosis and treatment, to allow early detection to continue to save lives while at the same time ensuring that we are placing the utmost value on preserving quality of life as well by minimizing unnecessary treatment and potential side effects. We don’t have a fool-proof solution yet, but we are committed to directing resources and research to answering the question and implementing the results.

Dr. Stuart Edmonds joined Prostate Cancer Canada in February 2011. During his time at the organization he has spearheaded the launch of the Research Strategic Plan, providing the direction for research and survivorship activities for 2012-2015. From this plan, PCC has launched numerous new research programs based on the key pillars: Collaboration, Innovation and Talented People. Dr. Edmonds has also instituted a fair and transparent peer review process to steward and safeguard funds raised in support of prostate cancer research and to ensure that only the most promising, high quality research is funded. Prior to joining PCC Dr. Edmonds held leadership roles at the Canadian Cancer Society, the Canadian Partnership Against Cancer, the Canadian Cancer Research Alliance and the National Cancer Institute of Canada. Dr. Edmonds holds a doctorate in pharmacology from Oxford University.
Posted: 2013-11-26 3:38:17 PM
Filed under: Stuart Edmonds, T2:ERG, urine test

comments powered by Disqus


Local Hero Award A Survivorship Action Partnership Active adt advanced Alex Baumann Annual Moose & Goose Club Black Tie Dinner antigen ASAP athlete awareness Beam biopsies biopsy Bismar blood BOSSS Tournament Boutros Brachytherapy Bristow british Buttyan Calgary Canada Cancer caregiver catheter CFL Chemotherapy cherry cnic columbia Conor Malone Cruisin’ For A Cure Canada Dad dads Dakar Rally day deprivation detection diagnosis digital dna do doctor don donate DRE early Early detection ED Edmonton Education erection eric Eskimos exam experience External family Father and Sons Xcanada Father’s Day Walk/Run FDiagnosis Football for Fred Chartrand funding fundraising genetics Golf Town Charity Classic health High-Intensity history hockey Hope Hormone international it Jack Layton Len Levesque lifelabs lottery loved mccormack Media men's moustache Movember MRI Murray Hill national navigator of Olivia Chow one ones partership Paul PCC PCC Atlantic PCCN pee Pilot Grant Program Plaid post-surgery pre-surgery prosate cancer Prostate prostate cancer Prostate Cancer Awareness Day Prostate Cancer Canada Prostate Cancer Canada Network Prostate Cancer Canada Network Conference prostatecancer Prostatectomy Protect the 5 Hole PSA PSA blood test PSA levels PSA test PSA value psatest Radiation Radical radioligand raffle Ralph Randy Remington Randy Remington Charity Golf Classic recovery rectal remember Research researcher Resources Rhodes Ride Rising risk road Rob robyn Rocco Rossi rock Rocktheroadraffle run Scotiabank StickIt Scotiabank Stick-It screened screening sexuality Sled specific Star step Steve Jones story Stuart Edmonds support surgery Surveillance survivor survivors survivorship programs T2:ERG Tarek test testing the The Breast Friends The Randy Remington Golf Classic Therapy TIEd Together TIEd Together photo exhibit Treatment tumours up urine urine test urologist volunteer volunteering Volunteerism volunteers Wake Up Call Breakfast walk week winner World


December 2019(1)
November 2019(3)
October 2019(2)
September 2019(7)
August 2019(6)
July 2019(5)
Juin 2019(0)
May 2019(5)
April 2019(4)
Mars 2019(5)
February 2019(6)
January 2019(4)
December 2018(1)
November 2018(1)
October 2018(3)
September 2018(4)
July 2018(2)
June 2018(1)
April 2018(2)
February 2018(2)
December 2017(2)
October 2017(1)
April 2017(2)
February 2017(1)
December 2016(2)
July 2016(2)
May 2016(1)
March 2016(1)
December 2015(1)
November 2015(1)
September 2015(1)
July 2015(1)
June 2015(1)
April 2015(2)
March 2015(2)
February 2015(2)
January 2015(2)
December 2014(4)
November 2014(2)
August 2014(1)
July 2014(2)
May 2014(2)
April 2014(1)
December 2013(2)
November 2013(3)
October 2013(1)
September 2013(6)
August 2013(2)
September 2012(4)
August 2012(1)
June 2012(1)
April 2012(1)
March 2012(3)
February 2012(2)
January 2012(1)
October 2011(1)
June 2011(2)
January 2011(1)
November 2010(6)
October 2010(3)
September 2010(3)
August 2010(4)
July 2010(2)
February 2010(3)
January 2010(1)